Format
Items per page
Sort by

Send to:

Choose Destination

Links from PubMed

Items: 1 to 20 of 90

1.

Assessing proarrhythmic potential of drugs when optimal studies are infeasible.

Rock EP, Finkle J, Fingert HJ, Booth BP, Garnett CE, Grant S, Justice RL, Kovacs RJ, Kowey PR, Rodriguez I, Sanhai WR, Strnadova C, Targum SL, Tsong Y, Uhl K, Stockbridge N.

Am Heart J. 2009 May;157(5):827-36, 836.e1. doi: 10.1016/j.ahj.2009.02.020. Review.

PMID:
19376308
2.

Concentration-QT relationships play a key role in the evaluation of proarrhythmic risk during regulatory review.

Garnett CE, Beasley N, Bhattaram VA, Jadhav PR, Madabushi R, Stockbridge N, Tornøe CW, Wang Y, Zhu H, Gobburu JV.

J Clin Pharmacol. 2008 Jan;48(1):13-8. Review.

PMID:
18094216
3.

Update on the evaluation of a new drug for effects on cardiac repolarization in humans: issues in early drug development.

Salvi V, Karnad DR, Panicker GK, Kothari S.

Br J Pharmacol. 2010 Jan;159(1):34-48. doi: 10.1111/j.1476-5381.2009.00427.x. Epub 2009 Sep 23. Review.

4.

Drugs, QT interval prolongation and ICH E14: the need to get it right.

Shah RR.

Drug Saf. 2005;28(2):115-25. Review.

PMID:
15691222
5.
6.
7.

Electrocardiographic assessment for therapeutic proteins--scientific discussion.

Rodriguez I, Erdman A, Padhi D, Garnett CE, Zhao H, Targum SL, Balakrishnan S, Strnadova C, Viner N, Geiger MJ, Newton-Cheh C, Litwin J, Pugsley MK, Sager PT, Krucoff MW, Finkle JK.

Am Heart J. 2010 Oct;160(4):627-34. doi: 10.1016/j.ahj.2010.07.001. Review.

PMID:
20934555
8.
9.

Models for profiling the potential QT prolongation risk of drugs.

Muzikant AL, Penland RC.

Curr Opin Drug Discov Devel. 2002 Jan;5(1):127-35. Review.

PMID:
11865666
10.

Safety pharmacology and risk assessment.

Kinter LB, Valentin JP.

Fundam Clin Pharmacol. 2002 Jun;16(3):175-82. Review.

PMID:
12165065
11.

Early investigation of QTc liability: the role of multiple ascending dose (MAD) study.

Shah RR, Morganroth J.

Drug Saf. 2012 Sep 1;35(9):695-709. doi: 10.2165/11634810-000000000-00000. Review.

PMID:
22845313
12.

Pharmacogenetic issues in thorough QT trials.

Judson RS, Salisbury BA, Reed CR, Ackerman MJ.

Mol Diagn Ther. 2006;10(3):153-62. Review.

PMID:
16771601
13.

Assessment of QT liabilities in drug development.

Arrigoni C, Crivori P.

Cell Biol Toxicol. 2007 Jan;23(1):1-13. Epub 2006 Sep 29. Review.

PMID:
17013551
14.

Use of ANOVA to estimate inter- and intra-reader variability for a group of readers in thorough QT/QTc studies.

Natekar M, Mahajan V, Satra A, O'Kelly M, Karnad DR.

Clin Pharmacol Ther. 2008 Mar;83(3):489-91. doi: 10.1038/sj.clpt.6100481. Epub 2008 Jan 9. Review.

PMID:
18183035
15.

Molecularly targeted oncology therapeutics and prolongation of the QT interval.

Strevel EL, Ing DJ, Siu LL.

J Clin Oncol. 2007 Aug 1;25(22):3362-71. Review.

PMID:
17664484
16.

The dog's role in the preclinical assessment of QT interval prolongation.

Gralinski MR.

Toxicol Pathol. 2003 Jan-Feb;31 Suppl:11-6. Review.

17.

The thorough QT/QTc study 4 years after the implementation of the ICH E14 guidance.

Darpo B.

Br J Pharmacol. 2010 Jan;159(1):49-57. doi: 10.1111/j.1476-5381.2009.00487.x. Epub 2009 Nov 18. Review.

18.

Challenges of characterizing proarrhythmic risk due to QTc prolongation induced by nonadjuvant anticancer agents.

Sarapa N, Britto MR.

Expert Opin Drug Saf. 2008 May;7(3):305-18. doi: 10.1517/14740338.7.3.305 . Review.

PMID:
18462188
19.

Preclinical cardio-safety assessment of torsadogenic risk and alternative methods to animal experimentation: the inseparable twins.

Dumotier BM, Georgieva AV.

Cell Biol Toxicol. 2007 Jul;23(4):293-302. Epub 2007 Jan 10. Review.

PMID:
17216548
20.

Magnetocardiography for pharmacology safety studies requiring high patient throughput and reliability.

Steinhoff U, Knappe-Grueneberg S, Schnabel A, Trahms L, Smith F, Langley P, Murray A, Koch H.

J Electrocardiol. 2004;37 Suppl:187-92. Review.

PMID:
15534839
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk